May 13, 2013
Cadwalader, Wickersham & Taft LLP, a leading counselor to global financial institutions and corporations, announced today that client Élan Corporation, plc, a biotechnology company headquartered in Ireland, will purchase from Theravance, Inc. a 21% participation interest in potential future royalty payments related to four respiratory programs partnered with GlaxoSmithKline plc: RELVAR™ ELLIPTA™/BREO™ ELLIPTA™, AORO™ ELLIPTA™, MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist) monotherapy (GSK961081) and vilanterol (VI) monotherapy. In exchange for the participation interest, Élan will make a one-time cash payment to Theravance of $1.0 billion.
The Cadwalader team is led by Christopher Cox (Corporate), Ira Schacter (Corporate) and special counsel Aly El Hamamsy (Corporate) in New York; and Angus Duncan (Capital Markets) and Adam Blakemore (Tax) in London.
In April, Cadwalader also advised Élan in the restructuring of its Tysabri® collaboration with Biogen Idec. On closing of the transaction, Élan received a cash payment of $3.25 billion, together with a double-digit, tiered royalty right on future worldwide net sales of Tysabri®.
our latest insights on the impact of COVID-19 to help you navigate this unprecedented environment.
Patrick Quinn and Ruth Merisier discuss the legal profession, working at Cadwalader, and more.
Selections to the Lawdragon 500 are limited to no more than 500 lawyers in the country.
Our latest podcast covers the legacy of the “Car Wash” investigation and how Brazil fits into the global landscape of white-collar crime enforcement.